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Poster Session I S235initiated when the peripheral blood CD34 cell count was.7/ul. The
target total CD34 cell collection was 5  106 cells, and ‘‘poor mobi-
lizers’’ were defined as pts unable to collect this target in 1-2 days of
collection.
Results: Prior to mobilization, 80 (53%) pts had previously re-
ceived thalidomide, and 29 (19%) additional pts had previously
been exposed to lenalidomide, with a median treatment duration
of 6 months. All 152 pts (100%) successfully collected with one
mobilization, 143 pts (94%) successfully collected in a single
day, and the median total number of CD34 cells collected was
12  106. 61% of pts collected on D + 11 and the rest between
D + 7 and D + 13. Only 2 pts (1%) were subsequently categorized
as poor mobilizers, requiring 3 and 4 days to collect. 27 out of 29
pts who had received lenalidomide previously were found to be
good mobilizers. The median time to neutrophil engraftment
was 11 days, and the median time to a sustained platelet
count. 20,000 without transfusions for 7 days was 16 days. 31
(20%) pts required at least one supportive transfusion during
the mobilization process, and a total of 26 (17%) pts required
treatment for fevers. No pts developed MDS or AML. Neither
age, prior imid exposure, nor any other variables were associated
with poor mobilization or engraftment.
Conclusion: VP-16 and G-CSF is an effective and safe mobilization
regimen for pts with MM undergoing ASCT, producing excellent
stem cell yield with a minimum of pheresis procedures. With this
regimen, neither age nor prior imid exposure appear to adversely im-
pact stem cell collection.207
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Introduction: T-cell non-Hodgkins lymphomas (T-NHL) com-
prise a heterogeneous array of clinical and pathologic entities.
Among aggressive NHL, T cell phenotype is a poor risk factor. Cur-
rently, there is no universal standard of care regarding therapy. Re-
lying on evidence supporting a graft-versus-lymphoma (GVL) effect
in these diseases, investigators have used allogeneic transplant (al-
loHSCT) to treat T-NHL. Data regarding outcomes following al-
loHSCT for these patients remains limited.
Methods: We performed a retrospective analysis of 30 consecu-
tive patients (mean age 52, range 5-68) who received alloHSCT
for T-NHL at MSKCC, between Jan 1992 and Aug 2008. His-
tologies included anaplastic large cell (4 ALK -, 4 ALK+), an-
gioimmunoblastic (3), hepatosplenic gamma-delta (5), HTLV-1
associated (1), mycosis fungoides (2), NK/T (2), subcutaneous
panniculitis-like T-cell lymphoma (3), peripheral T cell lym-
phoma, NOS (6). Preparative regimens were ablative (9) or non-
ablative (21), grafts were unmodified (15) or ex-vivo T cell
depleted (TCD) (15). IPI, PIT and disease status were assessed
directly pre alloHSCT. Survival was estimated by the Kaplan-
Meier method, and the cumulative incidence function estimated
the probability of time to disease relapse (DR). Log-rank test
and Gray’s test were used respectively to determine whether sur-
vival and cumulative incidence functions differed by covariates of
interests.Results: Median follow up for survivors was 38 months. Two-year
overall survival (OS) was 60% (95% CI: 40-80). Log-rank test did
not reveal an association between OS and prior autoSCT, IPI,
PIT, TCD, disease status or degree of myeloablation. Pre-salvage
MIB-1/Ki-67\25% was associated with improved OS
(p5 0.007). The cumulative incidence of DR at 6 months was
30%. There were no associations between cumulative incidence of
DR and IPI, TCD, disease status, degree of myeloablation and
MIB-1/Ki-67 score.
Discussion: Two-year OS and DR at 1 year are favorable in this
population of T-NHL patients with 47% in durable remission.
Pre-salvage MIB-1/Ki-67\25% appears to be predictive of OS.
However, the ability to test for associations with clinical factors
and outcomes is limited by our small sample size and low number
of events. This study provides further support for prospective al-
loHSCT T-NHL trials including use and evaluation of prognostic
biomarkers like MIB-1/Ki-67.208
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Introduction: There remains little consensus about the best means
for mobilizing stem cells prior to ASCT. Cytokine alone, usually G-
CSF, provides easy scheduling while the combination approaches
generally provide higher cell yields and additional cytoreduction. Be-
cause of its value as a cytoreductive agent, and its lack of stem cell
damaging properties or other toxicities, we investigated the use of
mid-dose VP-16 plus G-CSF as a mobilizing regimen.
Methods: Between May 2004 and June 2009, 288 pts with the fol-
lowing diseases were mobilized with VP-16 (375 mg/m2 on D#1
and D#2) and G-CSF (5mcg/kg twice daily from D#3 through the
final day of collection): MM (152), Non-Hodgkin Lymphoma (98),
and Hodgkin Disease (38). In 14 pts, one dose of Rituximab
(375 mg/m2) was also given on D#1. 122 pts were female, 166
were male, and median age was 54 yrs (range 19-72). Stem cell col-
lection was initiated when the peripheral blood CD34 cell count
was more than 7/ul. The target total CD34 cell collection was 5 
106.
Results: Among all pts, 279 (97%) had stem cells successfully
collected after one mobilization. 9 pts (all with lymphoma) re-
quired more than one mobilization or bone marrow harvest for
yields less than 2  106. 14% of all pts required IV antibiotics
or hospitalization for fevers, and 32% of all pts needed at least
one RBC or platelet transfusion. One pt developed secondary
MDS. The median number of days collecting stem cells was 1
for MM pts and 2 for lymphoma pts, and the median total num-
ber of CD34 cells collected was 12  106 for MM pts and 6 
106 for lymphoma pts. 94% of MM pts and 43% of lymphoma
pts collected in a single day. The median time to neutrophil en-
graftment was 11 days for all pts, and the median time to a sus-
tained platelet count. 20,000 without transfusions for seven days
or longer was 16 days for MM pts and 15 days for lymphoma
pts. ‘‘Poor mobilizers’’ were defined as pts who failed to collect
5  106 cells in one or two days, and included 19% of all pts.
1% of MM pts and 40% of lymphoma pts were ‘‘poor mobi-
lizers’’(p\0.001). The pre-mobilization white blood count
(p5 0.01), platelet count (p5 0.006) and a CD34 count less
than 26/ul (p\0.001) were associated with poor mobilization
in lymphoma pts.
Conclusion: VP-16 and G-CSF is an effective and safe mobiliza-
tion regimen for pts undergoing ASCT with a low incidence of
fevers or need for supportive transfusions. A CD34 count\26/ul
in lymphoma pts appeared to predict for poor mobilization.
